Evercore Notes Humana's (HUM) Long-Term Earnings Growth Despite Medium-Term Uncertainty

Humana Inc. (NYSE:HUM) ranks among the stocks with low beta that can beat market volatility. On September 22, Evercore ISI began coverage of Humana Inc. (NYSE:HUM) with an In Line rating and a $295 price target, emphasizing the company’s medium-term concerns as well as its potential for long-term earnings growth.

Evercore ISI stated that “after 2028, Humana Inc. (NYSE:HUM) has the right mix of assets to grow adjusted EBIT at an LDD rate (and EPS likely at a mid-teens CAGR),” despite the medium-term outlook being “less clear.”

With an estimate that “~70%+ of MA members” might be enrolled in 4-Star or higher plans by 2028, the firm praised management’s aim to return top-quartile Stars performance, calling it “reasonable.”

Although Evercore ISI is not expecting a Stars impact in 2027, it stated that this would be “a meaningful tailwind to EPS.”

Humana Inc. (NYSE:HUM) is focused on improving health and well-being by providing a variety of healthcare benefits to its medical and specialty members. These include fully insured medical and specialty health insurance that covers vision, dental, and supplemental health benefits.

While we acknowledge the potential of HUM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.